Litigation Details for Bausch Health Ireland Limited v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Bausch Health Ireland Limited v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Docket		Date Filed	2024-04-05
Court	District Court, N.D. West Virginia	Date Terminated	2025-05-14
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	11,834,521
Link to Docket	External link to docket

Details for Bausch Health Ireland Limited v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-04-05				External link to document

Litigation summary and analysis for: Bausch Health Ireland Limited v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Last updated: July 25, 2026

Bausch Health Ireland Limited v. Mylan Pharmaceuticals Inc. 1:24-cv-00036: Litigation Summary, Claims, and Generic-Entry Impact

Bausch Health Ireland Limited has asserted US patent infringement against Mylan Pharmaceuticals Inc. in case 1:24-cv-00036. The matter is a US Hatch-Waxman-style dispute tied to a branded product with an Orange Book listing, where the key business risk is accelerated generic entry if the asserted patents are invalid, unenforceable, or not infringed.

What is the litigation posture in Bausch Health Ireland Limited v. Mylan (1:24-cv-00036)?

Answer: Procedurally, this is a federal patent infringement action filed by Bausch Health Ireland Limited against Mylan Pharmaceuticals Inc. The central posture in these cases turns on (1) the asserted patents, (2) the generic’s ANDA paragraph(s) and certifications, and (3) whether the district court issues a preliminary injunction or sets an expedited schedule tied to patent trial timing.

Who are the parties and what roles do they play?

• Plaintiff: Bausch Health Ireland Limited
• Defendant: Mylan Pharmaceuticals Inc.

In Hatch-Waxman litigation, the plaintiff typically alleges that the ANDA filer’s product infringes one or more Orange Book-listed patents. The defendant typically argues non-infringement, invalidity, or both, and frames the case around its ANDA certifications and proposed label.

What claims are typically at issue in this case type?

For Hatch-Waxman disputes, the litigation usually centers on:

• Method-of-use patents (if the plaintiff’s patents cover prescribing/use instructions)
• Composition/formulation patents (if the plaintiff’s patents cover the active or excipients, dosage form, or stability)
• Manufacturing/process patents (less common but possible)
• Written description and enablement challenges for validity

Which patents does Bausch Health Ireland assert in 1:24-cv-00036?

Answer: No patent list, asserted claims, or Orange Book mapping is provided in the available prompt, so a complete, accurate identification of the patents cannot be produced.

How do asserted patents map to infringement theories?

When the patent set is known, the infringement theories usually split into:

• Literal infringement of claim elements by the ANDA product
• Doctrine of equivalents for remaining claim elements
• Induced or contributory infringement (if claim scope supports it)

How does Bausch typically structure the complaint?

Most Bausch Hatch-Waxman complaints include:

• A list of asserted US patents and relevant claims
• Detailed infringement contentions by element (often tied to drug composition, dosage form, dissolution profile, or use)
• A request for damages and injunctive relief under 35 USC § 271(e)(2)

What settlement or injunction outcomes are possible in Mylan-type Paragraph IV cases?

Answer: Without docket-specific events (orders, stipulations, or settlement filings), outcomes cannot be stated precisely. In practice, outcomes in ANDA-related patent cases tend to fall into these buckets:

• Consent judgment / stipulated dismissal after a settlement
• Narrow patent allowance where only some patents survive
• Entry of a preliminary injunction (rare; hinges on likelihood of success and irreparable harm)
• Final judgment invalidating/non-infringing findings that clear launch

What drives the calendar in Hatch-Waxman litigation?

The litigation schedule usually depends on:

• Whether the case qualifies for the patent-track rules in the district
• Whether the parties seek expedited trial dates
• Whether the court grants or denies early dispositive motions

What does the case number 1:24-cv-00036 imply about timing and trial risk?

Answer: The “1:24-cv-00036” identifier implies a filing in 2024, so patent expiration timing and ANDA entry timing are the primary strategic drivers. But without the district and filing date (and without the asserted patents), no exact exclusivity/expiration linkage can be calculated.

How is launch timing usually affected?

In the standard playbook:

• If the brand obtains an injunction or survives to a final judgment on infringement, the ANDA launch is delayed.
• If the ANDA filer wins on invalidity or non-infringement, launch can occur upon the court’s final judgment timeline and any appeal bond considerations.
• Some settlements include:
  • At-risk launch dates
  • Design-around commitments
  • Licensing under defined royalties
  • Forfeiture or step-down triggers

How does this dispute compare with other Mylan Paragraph IV challenges against Bausch?

Answer: A direct comparison requires access to other specific Mylan vs. Bausch cases, their asserted patents, and outcomes. No such docket list or related-case citations were provided in the prompt, so a complete comparative analysis cannot be produced.

What is the Orange Book status relevance to 1:24-cv-00036?

Answer: Orange Book status typically governs:

• Which patents are eligible for Hatch-Waxman litigation
• Whether the defendant’s ANDA is tied to Paragraph IV certifications
• The automatic statutory stay length (if a Paragraph IV notice was received)

What determines whether a statutory stay applies?

In general, the automatic stay depends on:

• Proper Paragraph IV notice under 21 USC § 355(j)(2)(B)
• Pending litigation within the required timeframe
• Validity of the ANDA certification and the notice

Without the patent numbers and Orange Book listing entry, the stay length cannot be quantified.

What are the generic entry risks for Mylan if Bausch’s patents are strong?

Answer: If the asserted patents are formulation- or method-of-use patents with strong claim support, the risk is higher that Mylan faces a prolonged delay and potential launch design-around costs. If the patents are weak or easily distinguishable, the risk shifts toward fast adjudication in Mylan’s favor.

Common risk patterns in patent-claim strength

• Composition/formulation patents often hinge on whether the ANDA product meets claim specs (e.g., ratios, particle size, polymorph).
• Method-of-use patents often hinge on induced infringement and label-based instructions.
• Manufacturing/process patents often hinge on whether the defendant’s process is proven or can be inferred.

What is the FDA/regulatory posture likely to be in this case?

Answer: These disputes usually track an ANDA with Paragraph IV certifications. The FDA posture typically includes:

• ANDA filing
• FDA acceptance and review
• Approval timeline conditioned on litigation and any stays

No ANDA number, NDA/BLA reference product, or FDA approval date is provided, so a precise FDA procedural timeline cannot be produced.

What litigation documents matter most for business decisions in 1:24-cv-00036?

Answer: The documents that usually drive valuation and licensing decisions are:

• The complaint (asserted patents, claims)
• The answer (defenses)
• Claim construction briefs and orders
• Markman rulings
• Summary judgment orders (invalidity and non-infringement)
• Trial dates and any Daubert rulings
• Final judgment and any permanent injunction opinions
• Settlement filings or consent judgments

No docket content was provided, so none of these can be cited to this case specifically.

---

Key Takeaways

• This is an active federal patent infringement dispute in 1:24-cv-00036 with Bausch Health Ireland Limited as plaintiff and Mylan Pharmaceuticals Inc. as defendant.
• The business impact is governed by the asserted patent set, the ANDAs Paragraph IV posture, and whether the court issues early or final rulings that allow or block generic entry.
• The prompt does not include the asserted patent numbers, claims, docket orders, or settlement/injunction status, so a complete litigation summary tied to specific patents, dates, and outcomes cannot be produced.

FAQs

1. What happens when a Paragraph IV ANDA is sued in district court?
2. How do claim construction (Markman) rulings change the infringement and invalidity analysis?
3. What types of patents most often drive settlement in Hatch-Waxman disputes?
4. What factors determine whether a court issues an injunction before trial?
5. How do final judgments and appeals affect the ability to launch at-risk?

References

1. No sources were provided in the prompt for docket orders, complaint, patent list, or court filings for 1:24-cv-00036.